Investors back drug sector reporting guide
The Global reporting initiative (GRI) should develop sustainability reporting guidelines for pharmaceutical firms, according to leading socially responsible investment manager Henderson global investors. The recommendation comes in a report on corporate social responsibility (CSR) among drug makers. Henderson welcomes "positive shifts" on CSR but says a "responsibility deficit" remains. Establishment of a common reporting framework is among five priority actions it recommends. GRI has already developed sector-specific reporting guidelines for several other industries in addition to its generic guidance (EED 11/09/09). See Henderson report.
The full text of this article is only available to subscribers and free trialists. To login,please enter your email address and subscriber access code below.